Martin Dietrich, MD, PhD

Articles

Choosing a Molecular Testing Panel for Solid Tumors

September 6th 2022

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

Currently Targetable Mutations in Lung and Breast Cancer

September 6th 2022

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer

September 3rd 2022

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.

PD-L1 Expression and IO Therapy in Lung and Breast Cancer

September 3rd 2022

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Using Molecular Testing to Guide Treatment Decisions

August 29th 2022

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

Available Molecular Tests for Solid Tumors

August 29th 2022

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

Unmet Needs and Future Directions in the Management of CIM

July 22nd 2022

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

An Overview of Trilaciclib Safety and Patient QOL Outcomes

July 22nd 2022

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC

July 15th 2022

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Myeloprotective Benefit of CDK4/6 Inhibition in ES-SCLC

July 15th 2022

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Prophylactic Approaches to the Management of CIM in ES-SCLC

July 8th 2022

Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.

An Overview of Chemotherapy-Induced Myelosuppression in ES-SCLC

July 8th 2022

Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.

Closing Expert Perspectives on Treatment in Advanced NSCLC

June 2nd 2022

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

June 2nd 2022

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Recent Advances in Treatment of ROS1-Rearranged NSCLC

May 25th 2022

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Updates in Treatment of NSCLC with ALK Rearrangements

May 25th 2022

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.

Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice

May 17th 2022

A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.

Recent Advances in Treatment of NSCLC with NTRK Fusions

May 11th 2022

Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.

Treatment of KRAS G12C Mutant NSCLC

May 11th 2022

Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC

May 5th 2022

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.